According to ESCAT classification [22], the majority of molecular alterations were ESCAT IV (71%) with only one patient with ESCAT I molecular alteration (a lung adenocarcinoma with RET translocation) and 22 patients with ESCAT II (14.5%) molecular alteration (mainly pancreatic cancer with KRAS host spot mutation). This evidence concerns the gene RET and familial pancreatic carcinoma.